Metabolism of fluorine-containing drugs

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 443-470

  Park, B K ^a   Kitteringham, N R ^a   O'Neill, P M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Defluorination; Drug design; Drug metabolism; Drug safety; Drug toxicity; Metabolic stability

Indexed keywords

FLUORINE;

DRUG ACTIVITY; DRUG DESIGN; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; FLUORINE COMPOUNDS; HUMANS; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 0035038661     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.443     Document Type: Review

References (109)

1. Recent advances in the biomedicinal chemistry of fluorine-containing compounds
2. Some influences of fluorine in bioorganic chemistry
3. Aspects of the medicinal chemistry of fluoroorganic compounds. Part II
4. Aspects of the medicinal chemistry of fluoroorganic compounds. Part I
5. 19F-NMR spectroscopy and directly coupled HPLC-NMR-MS
6. 19F-MRS studies of fluorinated drugs in humans
7. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action
8. Synthesis and pharmacological evaluation of enantiomerically pure 4-deoxy-4-fluoromuscarines
9. Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: Effect of stereochemistry on fluorine-induced adrenergic selectivities
10. 18F]fluoropropranolol, a lipophilic ligand for the beta-adrenergic receptor
11. Effects of fluorine substitution on drug-metabolism - Pharmacological and toxicological implications
12. 2,6-Difluorophenol as a bioisostere of a carboxylic acid: Bioisosteric analogues of gamma-aminobutyric acid
13. Synthesis and evaluation of novel fluorinated methotrexate derivatives for application to rheumatoid arthritis treatment
14. Conformational energies of 2-fluoroethanol and 2-fluoroacetaldehyde enol - Strength of the internal hydrogen-bond
15. How good is fluorine as a hydrogen bond acceptor?
16. Synthesis and adrenergic activity of ring-fluorinated phenylephrines
17. Synthesis of estrone-3-sulfate analogues bearing novel nonhydrolyzable sulfate mimetics
18. Synthesis and characterization of a new fluorine substituted nonionic dinucleoside phosphonate analog, P-deoxy-P-(difluoromethyl)thymidylyl(3′-5′)thymidine
19. 3′,3′-difluoro-3′-deoxythymidine - Comparison of antihiv activity to 3′-fluoro-3′-deoxythymidine
20. Isopolar vs isosteric phosphonate analogs of nucleotides
21. Does ammonia hydrogen-bond
22. Steric effects. A study of a rationally designed system
23. Chiral synthesis via organoboranes.38. Selective reductions.48. Asymmetric reduction of trifluoromethyl ketones by B-chlorodiisopinocamphenylborane in high enantiomeric purity
24. Mechanism of the toxicity of the active constituent of Dichapetalum cymosum and related compounds
25. The effect of fuorine substitution on the physicochemical properties and the analgesic activity of paracetamol
26. Conformational analysis. 28. OH...F hydrogen bonding and the conformation of trans-2-fluorocyclohexanol
27. Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols
28. Oxidative dehalogenation of 2-fluoro-17α-ethynyloestradiol in vivo. A distal structuremetabolism relationship of 17α-ethynylation
29. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy
30. 19F]-nuclear magnetic resonance spectroscopy in vivo
31. 18F]trovafloxacin in healthy human subjects studied with positron emission tomography
32. Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils
33. Classification and structureactivity relationships of fluoroquinolones
34. Synthesis and properties of 7,7-difluoro derivatives of the 2,6-dioxa[3.1.1]bicycloheptane ring-system present in thromboxane-a2
35. Difluorothromboxane-A2 and stereoisomers - Stable derivatives of thromboxane-A2 with differential-effects on platelets and blood-vessels
36. 10,10-Difluoro-13dehydroprostacyclin: A chemically and metabolically stabilized potent prostacyclin
37. Prostaglandin chemistry. 20. Synthesis of chemically stable prostacyclin analogs
38. Metabolism of 11-oxygenated steroids. 3. Some 1-dehydro and 9 alpha-fluoro steroids
39. Cortisol metabolism by human liver in-vitro. 4. Metabolism of 9-alpha-fluorocortisol by human liver-microsomes and cytosol
40. Catecholestrogens as mediators of carcinogenesis - Correlation of aromatic hydroxylation of estradiol and its fluorinated analogs with tumor-induction in syrian-hamsters
41. The metabolism of 2- and 4-fluoro-17 β-estradiol in the rat and its implications for estrogen carcinogenesis
42. The metabolism of 16-fluoroestradiols in vivo: Chemical strategies for restricting the oxidative bio-transformations of an estrogen-receptor imaging agent
43. The nucleotides of fluorinated pyrimidines and their biological activities
44. Fluphenazine pharmacokinetics and therapeutic response
45. Molecular orbital-based quantitative structure reactivity relationship for the cytochrome P450-catalyzed 4-hydroxylation of halogenated anilines
46. Occurrence of the NIH shift upon the cytochrome P450-catalyzed in vivo and in vitro aromatic ring hydroxylation of fluorobenzenes
47. Urinary metabolites of a novel quinoxaline nonnucleoside reverse transcriptase inhibitor in rabbit, mouse and human: Identification of fluorine NIH shift metabolites using NMR and tandem MS
48. Safety assessment of peroxide antimalarials: Clinical and chemical perspectives
49. Metabolism of the antimalarial endoperoxide Ro 42-1611 (arteflene) in the rat: Evidence for endoperoxide bioactivation
50. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl] -(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58-235): A designed, potent, orally active inhibitor of cholesterol absorption
51. Role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective
52. The carcinogenicity of fluoro derivatives of 10-methyl-1,2benzanthracene: 3′- and 4′-monofluoroderivatives
53. Metabolism and tumorigenicity of 7-fluorobenzo(a)pyrenes, 8-fluorobenzo(a)pyrenes, 9-fluorobenzo(a)pyrenes, and 10-fluorobenzo(a)pyrenes
54. Comparative mutagenicity, tumor-initiating activity, carcinogenicity, and in vitro metabolism of fluorinated 5-methylchrysenes
55. Characterization of 5-methylchrysene-1,2-dihydrodiol-3,4-epoxide-DNA adducts
56. Reactions of dihydrodiol epoxides of 5-methylchrysene and 5, 6-dimethylchrysene with DNA and deoxyribonucleotides
57. 2-Fluoroestradiol - Separation of estrogenicity from carcinogenicity
58. Acute liver necrosis following overdose of paracetamol
59. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen
60. The effect of fluorine substitution on the hepatotoxicity and metabolism of paracetamol in the mouse
61. Metabolism and antigenicity of amodiaquine in the rat
62. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine
63. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine
64. The effect of chemical substitution on the metabolic-activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse
65. 4-aminoquinolines - Past, present and future: A chemical perspective
66. Synthesis of the 8-aminoquinoline antimalarial 5-fluoroprimaquine
67. Is enflurane hepatotoxic?
68. Sevoflurane: Metabolism and toxicity
69. Methoxyflurane metabolism and renal dysfunction: Clinical correlation in man
70. Renal effects and metabolism of isoflurane in man
71. Inorganic fluoride nephrotoxicity: Prolonged enflurane and halothane anesthesia in volunteers
72. Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1
73. Pharmacokinetics of inhaled anesthetics in humans - Measurements during and after the simultaneous administration of enflurane, halothane, isoflurane, methoxyflurane, and nitrous-oxide
74. Metabolism of isoflurane in Fischer 344 rats and man
75. Human liver microsomal enflurane defluorination catalyzed by cytochrome-P-450 2E1
76. Clinical isoflurane metabolism by cytochrome P450 2E1
77. Biotransformation and hepatorenal function in volunteers after exposure to desflurane (I-653)
78. I-653 resists degradation in rats
79. Summary of the National Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis
80. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4
81. Identification of cytochrome P450 2E1 as the predominant enzyme catalysing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyfluorane
82. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis
83. Metabolism of the hydrochlorofluorocarbon 1,2-dichloro-1,1-difluoroethane
84. Pentahaloethane-based chlorofluorocarbon substitutes and halothane - Correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic-acid excretion with calculated enthalpies of activation
85. Metabolism and pharmacokinetics of selected halon replacement candidates
86. Designing safer chemicals: Predicting the rates of metabolism of halogenated alkanes
87. Influence of glutathione conjugation on the immunogenicity of dinitrophenyl derivatives in the rat
88. Conjugation of dinitrofluorobenzene to plasma proteins in vivo in the rat
89. Enzymatic rupture of a C-F bond
90. Hydroxylation of 4-fluoro-L-phenylalanine by phenylalanine hydroxylase results in L-tyrosine and fluoride ion
91. Fluoride elimination from substrates in hydroxylation reactions catalyzed by p-hydroxybenzoate hydroxylase
92. Role of cytochromes p-450 and flavin-containing monooxygenase in the biotransformation of 4-fluoro-N-methylaniline
93. Bioactivation of 4-fluorinated anilines to benzoquinoneimines as primary reaction-products
94. Metabolic defluorination of 5-fluoro-amodiaquine in the rat
95. Cytochrome P450-catalyzed oxidation of halobenzene derivatives
96. Spontaneous hydrolysis of 4-trifluoromethylphenol to a quinone methide and subsequent protein alkylation
97. 5-Fluorouracil: A pharmacological paradigm in the use of cytotoxics
98. The anticancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate
99. Fluorocitrate inhibition of aconitase: Relative configuration of inhibitory isomer by X-ray crystallography
100. Phosphorylation, antiHIV activity and cyto-toxicity of 3′-fluorothymidine
101. Comparisons of antihuman-immunodeficiency-virus activities, cellular-transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine
102. 2′-Fluoro-2′,3′-dideoxyarabinosyl-adenine - A metabolically stable analog of the antiretroviral agent 2′,3′-dideoxyadenosine
103. 2′-Beta-fluoro-2′,3′-dideoxyadenosine, lodenosine, in rhesus monkeys: Plasma and cerebrospinal fluid pharmacokinetics and urinary disposition
104. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase
105. Synthesis and biological evaluation of 2-fluoro-8-azaadenosine and related-compounds
106. 2-Fluoroformycin and 2-aminoformycin - Synthesis and biological-activity
107. A pilot study of FTC + ddI + Efavirenz in treatment-naive HIV-infected adult: A potent and convenient once-a-day HAART (ANRS 091 Trial)
108. South Africa to tighten control on drug trials after five deaths